Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven H Liang

Showing results (31-40 of 270) with videos related to

Pageof 27
Sort By:
ACS Medicinal Chemistry Letters|October 15, 2025
Development of Selective PARP1 Inhibitors for Treatment of CancerXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|August 20, 2025
The Development of Inhibitors for NLRP3 InflammasomeXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|February 19, 2025
Novel Tricyclic KRAS Inhibitors for the Treatment of CancerTaoqian Zhao, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Novel 5,6-Fused and 6,6-Fused Bicyclic Compounds as 15-Prostaglandin Dehydrogenase ModulatorsJian Rong, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]oxazolo[5,4-<i>f</i>]quinazoline-9,1'-cyclohexan]-7-one Scaffold for the Treatment of Chronic FatigueZhendong Song, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) ActivatorsXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|March 18, 2026
Krüppel-like Factor 2 (KLF2) Inducing Agents and Their Therapeutic ApplicationsLingxin Meng, Steven H Liang
ACS Medicinal Chemistry Letters|March 18, 2026
Synthesis of Novel USP1 Inhibitors and Their Uses in Treatment of USP1 Related DiseasesHaofeng Shi, Steven H Liang
ACS Medicinal Chemistry Letters|April 15, 2026
GHSR-Targeted PET Imaging ProbeRuihu Song, Steven H Liang
ACS Medicinal Chemistry Letters|May 20, 2026
Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases TreatmentYanwei Jiang, Steven H Liang
Pageof 27

Showing results (31-40 of 270) with videos related to

Sort By:
Pageof 27
ACS Medicinal Chemistry Letters|October 15, 2025
Development of Selective PARP1 Inhibitors for Treatment of CancerXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|August 20, 2025
The Development of Inhibitors for NLRP3 InflammasomeXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|February 19, 2025
Novel Tricyclic KRAS Inhibitors for the Treatment of CancerTaoqian Zhao, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Novel 5,6-Fused and 6,6-Fused Bicyclic Compounds as 15-Prostaglandin Dehydrogenase ModulatorsJian Rong, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]oxazolo[5,4-<i>f</i>]quinazoline-9,1'-cyclohexan]-7-one Scaffold for the Treatment of Chronic FatigueZhendong Song, Steven H Liang
ACS Medicinal Chemistry Letters|March 19, 2025
Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) ActivatorsXin Zhou, Steven H Liang
ACS Medicinal Chemistry Letters|March 18, 2026
Krüppel-like Factor 2 (KLF2) Inducing Agents and Their Therapeutic ApplicationsLingxin Meng, Steven H Liang
ACS Medicinal Chemistry Letters|March 18, 2026
Synthesis of Novel USP1 Inhibitors and Their Uses in Treatment of USP1 Related DiseasesHaofeng Shi, Steven H Liang
ACS Medicinal Chemistry Letters|April 15, 2026
GHSR-Targeted PET Imaging ProbeRuihu Song, Steven H Liang
ACS Medicinal Chemistry Letters|May 20, 2026
Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases TreatmentYanwei Jiang, Steven H Liang
Pageof 27